Condition: Recurrent Melanoma (Skin) · Metastatic Melanoma · Melanoma Stage IV · Sponsor: Perspective Therapeutics
In this first-in human, phase I/IIa study, the safety and efficacy of \[212Pb\]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated as a monotherapy and in combination with nivolumab in subjects with unresectable and metastatic melanoma.
This description comes directly from the study's public registry record.
ClinicalTrials at Perspectivetherapeutics · 206-676-0900 · clinicaltrials@perspectivetherapeutics.com
Always discuss trial participation with your own doctor first.
| University of California Irvine | Orange, California, United States | Recruiting |
| Mayo Clinic | Jacksonville, Florida, United States | Recruiting |
| University of Miami | Miami, Florida, United States | Recruiting |
| Sarasota Memorial Hospital | Sarasota, Florida, United States | Recruiting |
| University of Iowa | Iowa City, Iowa, United States | Recruiting |
| University of Kentucky | Lexington, Kentucky, United States | Recruiting |
| Mayo Clinic Rochester | Rochester, Minnesota, United States | Recruiting |
| Saint Louis University Hospital | St Louis, Missouri, United States | Recruiting |
| Washington University of St. Louis | St Louis, Missouri, United States | Recruiting |
| Nebraska Cancer Specialists | Omaha, Nebraska, United States | Recruiting |
| Fox Chase Cancer Center | Philadelphia, Pennsylvania, United States | Recruiting |
| UPMC Hillman Cancer Center | Pittsburgh, Pennsylvania, United States | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05655312